Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab

@article{GarcaCadenas2015ImpactOE,
  title={Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab},
  author={Irene Garc{\'i}a-Cadenas and Nelson Castillo and Rodrigo Martino and Pere Barba and Albert Esquirol and Silvana Novelli and Guillermo Ort{\'i} and Alexis Garrido and Sandy Saavedra and Christophe Moreno and Miquel Granell and J Rubio Briones and Salut Brunet and Françis Navarro and Ioana Ruiz and N{\'u}ria Rabella and D Valcarcel and Jorge Sierra},
  journal={Bone Marrow Transplantation},
  year={2015},
  volume={50},
  pages={579-584}
}
We monitored 133 high-risk allo-SCT recipients for 6 months after transplant for EBV reactivation by quantitative real-time PCR. Rituximab was given as pre-emptive therapy for viremia >1000 copies/mL. The 1-year cumulative incidence of EBV reactivation was 29.4% (95% confidence interval (CI): 18–40) in patients monitored due to initial high-risk characteristics (n=93) and 31.8% (95% CI: 19.7–44) in those followed because of the development of refractory GVHD (n=40). Overall response rate to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS